Sysmex (6869) · InitiativeHolding ended following sale of shares
Capital and business alliance with KAINOS Laboratories,Inc. concerning immunoassay diagnostic reagents
First written in FY2022. 1 of 3 entries say "Restated". Latest entry: FY2026.
3entries
5years
0from disclosures
How it moved
Same theme, other companies
Capital and business alliance with KAINOS Laboratories,Inc. concerning immunoassay diagnostic reagentsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026Holding ended following sale of sharesAnnual report
「The shares in KAINOS Laboratories,Inc. held by the Company were sold by tendering them in the tender offer.」
Sold all shares held in connection with the capital and business alliance with KAINOS by tendering them in the tender offer. The end of the capital and business alliance agreement was not expressly stated. - FY2024RestatedAnnual report
「The shares are held with the aim of contributing to sustained growth in corporate value by strengthening the collaborative framework through the capital and business alliance with KAINOS Laboratories,Inc.」
Reiterates the strengthening of the development and supply framework for immunoassay diagnostic reagents through the capital and business alliance with KAINOS. - FY2022First statedAnnual report
「February 2022: The company agreed to a capital and business alliance with KAINOS Laboratories,Inc. aimed at strengthening the development and production capabilities for diagnostic reagents in the immunoassay field.」
Agreed to a capital and business alliance with KAINOS Laboratories,Inc. to strengthen the development and production capabilities of diagnostic reagents in the immunoassay field.